Souhaitez-vous accéder aux communiqués récents ?

Ricavi netti consolidati per l’esercizio 2025 pari a € 2.618,4 milioni, +11,8% o +8,3% a perimetro omogeneo(3) e a cambi costantiEBITDA(1) pari a € 991,1 milioni, +14,5%, con un’incidenza sui ricavi...

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA +14.5%, ADJUSTED NET INCOME +14.5%

mRNA-3927 si inserisce strategicamente nel portafoglio delle malattie rare metaboliche di Recordati La collaborazione unisce l’expertise di Moderna nella tecnologia mRNA per i disturbi metabolicirari...

RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA

NEWS RELEASE RECORDATI FIRST NINE MONTHS 2025 RESULTS:REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION Consolidated...

NEWS RELEASE Milan, 23 October 2025 – Recordati, a global pharmaceutical company, announces today that Mike McClellan will join as its new Chief Financial Officer (CFO) as of January 1, 2026 and...

The 2026 Award is focused on research in paediatric oncology, specifically sarcomasPaediatric sarcomas are among the leading causes of cancer-related death in children, yet there has been little...

Consolidated net revenue of € 1,323.8 million in the first half of 2025, +11.7% or +7.8% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 496.3 million, +9.6%, margin on...

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE Vazkepa® supported by strong clinical data package and expected to contribute to...

Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 270.2 million, +10.7%, margin...